Huma Therapeutics, a global leader in AI-powered digital health platforms, has announced a dual move to accelerate its healthcare expansion: the acquisition of U.S.-based respiratory health company Aluna and a strategic growth partnership with Eckuity Capital.
The acquisition of Aluna—known for its FDA-cleared respiratory monitoring solutions and digital spirometry devices—bolsters Huma’s chronic care capabilities across asthma, COPD, and sleep apnea. Aluna’s integration into the Huma Cloud Platform will upgrade its classification to FDA Class II, granting enhanced clinical utility to its 150+ U.S. health system clients and extending support to over 500,000 respiratory care patients.
To support this and future acquisitions, Huma also entered a global partnership with Eckuity Capital. The firm will back Huma’s M&A roadmap, aiming to build a unified, AI-enabled digital infrastructure for healthcare and life sciences.
With regulatory clearances including FDA 510(k) and EU MDR Class IIb, Huma’s platform supports over 4,500 clinics across 70 countries. This expansion positions the company to better address the 40+ million respiratory patients in the U.S. alone.
Huma CEO Dan Vahdat said the move signals a new phase for the company’s ecosystem ambitions, while Eckuity’s Managing Partner Youssef Sebban noted the synergies will unlock significant value by elevating acquired companies on Huma’s infrastructure.
The transaction was legally advised by Goodwin Proctor for Huma, with Peak Technology Partners advising Aluna.
